ALC-0315
| ALC-0315 | |
|---|---|
| |
| IUPAC名 [(4-Hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate) | |
| 識別 | |
| CAS號 | 2036272-55-4 
|
| PubChem | 122666778 |
| ChemSpider | 103867294 |
| SMILES |
|
| 性質 | |
| 化學式 | C48H95NO5 |
| 摩爾質量 | 766.27 g·mol−1 |
| 密度 | 0.919±0.06 g·cm−3（20 °C）[1] |
| 溶解性（水） | 7.7×10−5 g·L−1（25 °C）[1] |
| 若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。 | |
ALC-0315是一種合成脂，為油狀物質。它是BioNTech和輝瑞的SARS-CoV-2疫苗和BNT162b2疫苗的賦形劑，為脂質納米顆粒（LNP）的四成分之一，LNP封裝並保護了藥物中脆弱的有效成分mRNA。[2][3]
在體內pH下，ALC-0315帶正電荷，它可以和帶負電荷的mRNA相互作用。[4]這些納米顆粒在體外和體內都可以促進核酸（如寡核苷酸或信使RNA）的吸收。[5][6]
合成
ALC-0315的合成方法如下：
參見
參考文獻
- ^ 1.0 1.1 Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 ([C] 1994-2021 ACD/Labs). Retrieved from SciFinder.
- ^ Michael McCoy. Lipids, the unsung COVID-19 vaccine component, Get Investment. Chemical and Engineering News. February 12, 2021.
- ^ Ryan Cross. Without These Lipid Shells, There Would Be No mRNA Vaccines for COVID-19. Chemical & Engineering News. 2021: 16–19. doi:10.47287/cen-09908-feature1.
- ^ Medicines and Healthcare products Regulatory Agency. Public Assessment Report: Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2 (PDF). 11 December 2020 [2021-05-30]. （原始內容 (PDF)存檔於2020-12-16）.
- ^ mRNA-based therapeutics — developing a new class of drugs （頁面存檔備份，存於互聯網檔案館）, Ugur Sahin, Katalin Karikó and Özlem Türeci, Nature Reviews Drug Discovery, 13, 759-780 (2014), doi:10.1038/nrd4278.
- ^ mRNA vaccines — a new era in vaccinology （頁面存檔備份，存於互聯網檔案館）, Norbert Pardi, Michael J. Hogan, Frederick W. Porter and Drew Weissman, Nature Reviews Drug Discovery, 17, 261-279 (2018), doi:10.1038/nrd.2017.243.
外部連結
- WIPO patent WO 2018/081480 A1 （頁面存檔備份，存於互聯網檔案館） - occurs as compound III-3.